Safety and efficacy of the long-term adjuvant treatment of primary intermediate- to high-risk malignant melanoma (UICC/AJCC stage II and III) with a standardized fermented European mistletoe (Viscum album L.) extract: Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland

Arzneimittel-Forschung/Drug Research

Volumn 55, Issue 1, 2005, Pages 38-49

  Augustin, Matthias ^a,d   Bock, Paul R ^b   Hanisch, Jürgen ^b   Karasmann, Marita ^b   Schneider, Berthold ^c  

^a UNIVERSITY OF FREIBURG   (Germany)

^b IFAG Basel AG   (Switzerland)

^c HANNOVER MEDICAL SCHOOL   (Germany)

^d UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

Iscador ; Melanoma; Mistletoe, comparative cohort study, efficacy, safety, survival; Viscum album L.

Indexed keywords

VISCUM ALBUM EXTRACT;

ADULT; AGED; ALLERGY; ALOPECIA; ANGIONEUROTIC EDEMA; ARTICLE; BRAIN METASTASIS; CANCER ADJUVANT THERAPY; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER MORTALITY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; ECZEMA; EPIDEMIOLOGICAL DATA; FATIGUE; FEMALE; FEVER; FOLLOW UP; HEADACHE; HISTOPATHOLOGY; HUMAN; KAPLAN MEIER METHOD; LONG TERM CARE; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MELANOMA; MULTICENTER STUDY; PANCREATITIS; POSTOPERATIVE CARE; PRACTICE GUIDELINE; PRURITUS; RASH; REGRESSION ANALYSIS; RISK ASSESSMENT; SLEEP DISORDER; TREATMENT OUTCOME; VISCUM ALBUM;

EID: 12944320296     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1296823     Document Type: Article

References (91)

1. Berwick, M., Weinstock, M. A., Epidemiology. Current trends. In: Balch, C. M., Houghton, A. N., Sober, A. J. (eds.), Cutaneous Melanoma. 4th ed. Quality Medical Publishing, St. Louis, Missouri (2003) p. 15-23,
2. Marks, R., Hill, D., The public health approach to melanoma control. Prevention and early detection. International Union against Cancer (UICC) (1992)
3. Jemal, A., Tiwari, R. C., Murray, T. et al., Cancer Statistics, 2004. CA Cancer J. Clin. 54, 8 (2004)
4. National Cancer Institute (USA). SEER Cancer Statistics Review 1975-2001. Internet publication 2003; URL: http://srab.cancer.gov/jointpoint/
5. Blum, A., Ellwanger, U., Garbe, C., Das maligne Melanom der Haut. Analyse der Daten des Zentralregisters Malignes Melanom der Deutschen Dermatologischen Gesellschaft 1983-1995. Krebsverband Baden-Württemberg e.V. (1996)
6. Blum, A., Garbe, C., Epidemiologie, Prävention und Nachsorge maligner Melanome. Onkologe 7, 18 (2001)
7. Garbe, C., Bertz, J., Orfanos, C. E., [Malignant melanoma in German-speaking countries in the 80's. Initial results of the central registry for malignant melanoma of the Germany Society of Dermatology in cooperation with the federal health office]. Hautarzt 38, 639 (1987)
8. Garbe, C., Epidemiologie des malignen Melanoms in Deutschland. In: Macher E, Bröcker EB, Kolde G, editors. Tumoren der Haut: Jahrbuch der Dermatologie 1994/1995, p. 113-120, Biermann, Stuttgart (1994)
9. Garbe, C., Blum, A., Epidemiology of cutaneous melanoma in Germany and worldwide. Skin Pharmacol. Appl. Skin. Physiol. 14, 280 (2001)
10. Schmid, M., Hölzel, D., Klinisch-epidemiologische Daten zum malignen Melanom aus dem Bereich des Tumorzentrums München. In: Volkenandt, M., Plewig, G. (eds.), Manual Maligne Melanome. Manuale des Tumorzentrums München ed. München, p. 2-6, W Zuckschwerdt Verlag, Munich (2000)
11. Balch, C. M., Soong, S. J., Gershenwald, J. E. et al., Prognostics factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on Cancer melanoma staging system. J. Clin. Oncol. 19, 3622 (2001)
12. Tsao, H., Atkins, M., Sober, A. J., Management of Cutaneous Melanoma. N. Engl. J. Med. 351, 998 (2004)
13. Davis, N. C., Herron, J. J., Queensland melanoma project: organization and plea for comparable surveys. Med. J. Aust. 1, 643 (1966)
14. Marks, R., Melanoma prevention: is it possible to change a population's behavior in the sun? Pigment Cell. Res. 7, 104 (1994)
15. Girgis, A., Campbell, E. M., Redman, S. et al., Screening for melanoma: a community survey of prevalence and predictors. Med. J. Aust. 154, 338 (1991)
16. Elwood, J. M., Gallagher, R., Skin cancer epidemiology study in the 1996. The Third Symposium on the Epidemiology of Melanoma and Non-melanocytic Skin Cancer. Melanoma Res. 7, 74 (1997)
17. Garbe, C., Buttner, P., Ellwanger, U. et al., [The Malignant Melanoma Central Register of the German Society of Dermatology 1983-1993. Epidemiologic developments and current therapeutic management of malignant melanoma of the skin]. Hautarzt 46, 683 (1995)
18. Stroebel, W., Schlagenhauff, B., Meie.r F. et al., Nachsorge bei Melanompatienten. In: Garbe, C. (ed.), Dermatologische Onkologie, p. 407-413, Springer Verlag, Berlin-Heidelberg etc. (1997)
19. Balch, C. M., Gershenwald, J. E., Buzaid, A. C. et al., Staging and Classification. In: Balch, C. M., Houghton, A. N., Sober, A. J. et al. (eds.), Cutaneous Melanoma. 4th ed, p. 55-76, Quality Medical Publishing, Inc., St. Louis, Missouri (2003)
20. Garbe, C., Büttner, R, Bertz, J., Die Prognose des primären malignen Melanoms. In: Orfanos, C. E., Garbe, C. (eds.), Das maligne Melanom der Haut. p. 41-59, Zuckschwerdt, Muncih (1990)
21. Haffner, A. C., Garbe, C., Burg, G. et al., The prognosis of primary and metastasising melanoma. An evaluation of the TNM classification in 2,495 patients. Br. J. Cancer 66, 856 (1992)
22. Garbe, C., Schadendorf, D., Malignes Melanom - neue Daten und Konzepte zur Nachsorge. Dtsch Ärzteblatt 100 (A 26) 1804 (2003)
23. Orfanos, C. E., Jung, E. G., Rassner, G. et al., [Position and recommendations of the Malignant Melanoma Committee of the German Society of Dermatology on diagnosis, treatment and after-care of malignant melanoma of the skin. Status 1993/94]. Hautarzt 45, 285 (1994)
24. Ross, M. I., Balch, C. M., Cascinelli, N. et al., Excision of primary melanoma. In: Balch CM, Houghton AN, Sober AJ, Soong Seng-jaw, editors. Cutaneous Melanoma. 4th ed, p. 209-230, Quality Medical Publishing Inc., St. Louis, Missouri (2003)
25. Schuchter, L. M., Haluska, F. G., Fraker, D. L. et al., Skin: Malignant Melanoma. In: Abeloff, M. D., Armitage, J. O., Lichter, A. S. et al. (eds.), p. 1317-1359, Clinical Oncology. Churchill Livingstone, New York-Edinbourough etc. (2000)
26. Thomas, J. M., Newton-Bishop, J., A'Hern, R. et al., Excision margins in high-risk malignant melanoma. N. Engl. J. Med. 350, 757 (2004)
27. Balch, C. M., Soong, S. J., Smith, T. et al., Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision margins for 740 patients with 1-4 mm melanomas. Ann. Surg. Oncol. 8, 101 (2001)
28. Lens, M. B., Dawes, M., Goodacre, T. et al., Excision Margins in the Treatment of Primary Cutaneous Melanoma: A Systematic Review of Randomized Controlled Trials Comparing Narrow vs. Wide Excision. Arch. Surg. 137, 1101 (2002)
29. Balch, C. M., Lange, J. R., Lymphatic mapping and sentinel node lymphadenectomy for cancer: an overview. Ann. Surg. Oncol. 8 (9, Suppl), 1S (2001)
30. Balch, C. M., Houghton, A. N., Sober, A. J. et al., Cutaneous Melanoma. 4th ed. Quality Medical Publishing, Inc., St. Louis, Missouri (2003)
31. Thompson, J. F., Morton, D. L., Kroon, B. B. (eds.), Textbook of Melanoma. Dunitz, London (2004)
32. Balch, C. M., Cascinelli, N., Sim, F. H., Elective lymph node dissection. In: Balch, C. M., Houghton, A. N., Sober, A. J. et al. (eds.), Cutaneous Melanoma. 4th ed, p. 379-395, Quality Medical Publishing Inc., St. Louis, Missouri, USA (2003)
33. Mohrle, M., Schippert, W., Rassner, G. et al., Is sentinel lymph node biopsy of therapeutic relevance for melanoma? Dermatology 209, 5 (2004)
34. Reintgen, D. S., Thompson, J. F., Gershenwald, J. E., Intraoperative mapping and sentinel node technology. In: Balch, C. M., Houghton, A. N., Sober, A. J. et al. (eds.), Cutaneous Melanoma. 4th ed, p. 353-377, Quality Medical Publishing Inc., St. Louis, Missouri (2003)
35. McMasters, K. M., Reinigen, D. S., Ross, M. I. et al., Sentinel lymph node biopsy for melanoma: controversy despite widespread agreement. J. Clin. Oncol. 19, 2851 (2001)
36. Ainslie, J., Peters, L. J., McKay, M. J., Radiotherapy for primary and regional melanoma. In: Balch, C. M., Houghton, A. N., Sober, A. J. et al. (eds.), Cutaneous Melanoma. 4th ed, p. 449-471, Quality Medical Publishing, Inc., St. Louis, Missouri (2003)
37. Agarwala, S. S., Kirkwood, J. M., Interferons and adjuvant therapy. In: Belch, Ch. M., Houghton, A. N., Sober, A. J. et al. (eds.), Cutaneous Melanoma. 4th ed, p. 605-21, Quality Medical Publishing Inc., St. Louis, Missouri (2003)
38. Atkins, M. B., The treatment of metastatic melanoma with chemotherapy and biologies. Curr. Opin. Oncol. 9, 205 (1997)
39. Atkins, M. B., Buzaid, A. C., Houghton, A. N., Chemotherapy and Biochemotherapy. In: Balch, C. M., Houghton, A. N., Sober, A. J. et al. (eds.), Cutaneous Melanoma. 4th ed, p. 589-604, Quality Medical Publishing, Inc., St. Louis, Missouri (2003)
40. Eggermont, A. M., Adjuvant therapy of malignant melanoma and the role of sentinel node mapping. Recent Results Cancer. Res. 157, 178 (2000)
41. Eggermont, A. M., Gore, M., European approach to adjuvant treatment of intermediate- and high-risk malignant melanoma. Semin. Oncol. 29, 382 (2002)
42. Garbe, C., Eigentier, T. K., [Therapy of malignant melanoma at the stage of distant metastasis]. Hautarzt 55, 195 (2004)
43. Kleeberg, U. R., Suciu, S., Brocker, E. B. et al., Final results of the EORTC 18871/DKG 80-1 randomised phase III trial. rIFN-alpha2b versus rIFN-gamma versus ISCADOR M versus observation after surgery in melanoma patients with either high-risk primary (thickness > 3 mm) or regional lymph node metastasis. Eur. J. Cancer 40, 390 (2004)
44. Schwartzentruber, D. J., Rosenberg, S. A., Interleukins. In: Belch, Ch. M., Houghton, A. N., Sober, A. J. et al. (eds.), Cutaneous Melanoma. 4th ed, p. 623-43, Quality Medical Publishing Inc., St. Louis, Missouri (2003)
45. Kim, C. J., Dessureault, S., Gabrilovich, D. et al., Immunotherapy for melanoma. Cancer Control 9, 22 (2002)
46. Kirkwood, J. M., Manola, J., Ibrahim, J. et al. A pooled analysis of eastern cooperative oncology group and intergroup trials of adjuvant high-dose interferon for melanoma. Clin. Cancer Res. 10, 1670 (2004)
47. Lens, M. B., Eisen, T. G., Systemic chemotherapy in the treatment of malignant melanoma. Expert Opin. Pharmacother. 5, 2205 (2003)
48. Lens, M. B., Dawes, M., Interferon Alfa Therapy for Malignant Melanoma: A Systematic Review of Randomized Controlled Trials. J. Clin. Oncol. 20, 1818 (2002)
49. Wolchok, J. D., Weber, J. S., Houghton, A. N. et al., Melanoma vaccines. In: Belch, Ch. M., Houghton, A. N., Sober, A. J. et al., Cutaneous Melanoma. 4th ed, p. 645-56, Quality Medical Publishing Inc., St. Louis, Missouri (2003)
50. Kienle, G. S., Kiene, H., Die Mistel in der Onkologie. Fakten und konzeptionelle Grundlagen. Schattauer, Stuttgart-New York (2004)
51. Büssing, A., Mistletoe. The Genus Viscum. Harwood Academic Publishers, Amsterdam (2000)
52. Simon, J. C., Untersuchungen einiger immunologischer Parameter bei Patienten mit malignem Melanom vor und unter Therapie mit Iscador PcHg oder Interferon alfa2a. Med. Dissertation, Albert-Ludwigs-Universität, Freiburg i. Br. (1986)
53. Bergen, E., Behandlungsstandards in der Therapie des malignen Melanoms mit Iscador. Universitäts-Hautklinik, Freiburg i. Br. (1998)
54. Hauschild, A., Therapie des malignen Melanoms - Qualitätssicherung und Perspektiven. Onkologe 2, 412 (1996)
55. Albarrán-Weick, M., Retrospektive Fall-Kontrollstudie zum Stellenwert der adjuvanten Therapie des malignen Melanoms mit Iscador PcHg. Albert-Ludwigs-Universität Freiburg i. Br. (1998)
56. Bock, P. R., Friedel, W. E., Hanisch, J. et al., Retrolective, Comparative, Epidemiological Cohort Study with Parallel Groups Design for Evaluation of Efficacy and Safety of Drugs with "Well-Established Use". Forsch. Komplementärmed. 11 (Suppl. 1), 23 (2004)
57. Schneider, B., Analysis of therapeutic efficacy in observational cohort studies. Cancer Chemother. Pharmacol. 47 (Suppl.), 35 (2001)
58. Schneider, B., Bock, P. R., [Epidemiological Cohort Studies. Analysis of the efficacy of drugs with observational studies]. Epidemiologische Kohortenstudien. Analyse der therapeutischen Wirksamkeit von Arzneimitteln. Schweiz. Zschr. GanzheitsMedizin 14, 400 (2002)
59. Feinstein, A. R., Clinical Epidemiology. The Architecture of Clinical Research. W.B. Saunders Company, Philadelphia (1985)
60. Hanisch, J., Bock, P. R., Karasmann, M., Standard operating procedures and the operational manual for retrolective cohort studies according to the IFAG-standard (Retrospect™), Manual. IFAG Basel AG (2000)
61. Andrews, E. B., Avorn, J., Bortuichek, E. A. et al., Guidelines for Good Epidemiology Practices for drug, device, and vaccine research in the United States. Internet publication 1996. http://www.harvard.edu/organizations/DDIL/ gep_PE.html
62. Bellach, B.-M., Leitlinien und Empfehlungen zur Sicherung von Guter Epidemiologischer Praxis (GEP). Bundesgesundheitsblatt 43, 468 (2000)
63. Benson, K., Hartz, A. J., A comparison of observational studies and randomized clinical trials. N. Engl. J. Med. 342, 1878 (2000)
64. Concato, I., Shah, N., Horwitz, R. I. et al., Randomized, controlled trials, observational studies, and the hierarchy of research design. N. Engl. J. Med. 342, 1887 (2000)
65. Feinstein, A. R., The role of observational studies in the evaluation of therapy. Stat. Med. 3, 341 (1984)
66. Hlatky, M. A., Califf, R. M., Harrell-FE, J. et al., Comparison of predictions based on observational data with the results of randomized controlled clinical trials of coronary artery by-pass surgery. J. Am. Coll. Cardiol. 11, 237 (1988)
67. Rosati, R. A., Lee, K. L., Califf, R. M. et al., Problems and Advantages of an Observational Data Base Approach to Evaluating the Effect of Therapy on Outcome. Circulation 65 (Suppl. II), 27 (1982)
68. Beuth, J., Ost, B., Pakdaman, A. et al., Impact of complementary oral enzyme application in the postoperative treatment results of breast cancer patients - results of an epidemiological multicenter retrolective cohort study. Cancer Chemother. Pharmacol. 47 (Suppl.), 45 (2001)
69. Bock, P. R., Friedel, W. E., Hanisch, J. et al., [Efficacy and safety of long-term complementary treatment with standardized European mistletoe extract (Viscum album L.) in addition to the conventional adjuvant oncologic therapy in patients with primary non-metastasized mammary carcinoma. Results from a multicenter, comparative, epidemiological cohort study in Germany and Switzerland]. Arzneim.-Forsch./Drug Res. 54, 456 (2004)
70. Popiela, T., Kulig, J., Hanisch, J. et al., Influence of a complementary treatment with oral enzymes on patients with colorectal cancers - an epidemiological retrolective cohort study. Cancer Chemother. Pharmacol. 47 (Suppl.), 55 (2001)
71. Sakalová, A., Bock, P. R., Dedik, L. et al., Retrolective cohort study of an additive therapy with an oral enzyme preparation in patients with multiple myeloma. Cancer Chemother. Pharmacol. 47 (Suppl.), 38 (2001)
72. Schumacher, K., Schneider, B., Reich, G. et al., [Post surgical complementary therapy of primary breast carcinoma with a lectin-standardized mistletoe extract - an epidemiological, controlled, multicenter, retrolective cohort study]. German J. of Oncol. 34, 106 (2002)
73. EU, European Parliament, Das Europäische Parlament, European Council, Der Rat der Europäischen Union. Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to human medicinal products. Official Journal of the European Communities L 311, 67-128 (2001)
74. German Cochrane Center. Evidence hierarchy. 2002; Internet Communication. URL: http://www.cochrane.de/deutsch/ccevidenzhierarchie.htm
75. Oxford Centre for Evidence-based Medicine. Levels of Evidence and Grades of Recommendation 2001; Internet Communication. URL: http://www.cebm.net/ levels_of_evidence.asp
76. Balch, C. M., Buzaid, A. C., Soong, S. J. et al., Final version of the American Joint Committee on Cancer staging system for cutaneous melanoma. J. Clin. Oncol. 19, 3635 (2001)
77. Balch, C. M., Soong, S. J., Atkins, M. B. et al., An Evidence-based Staging System for Cutaneous Melanoma. CA Cancer J. Clin. 54, 131 (2004)
78. UICC, UICC, TNM Classification of malignant tumors, 5th ed., John Wiley & Sons, New York (1997)
79. NCI, NIH, DCTD, DHHS. Common Toxicity Criteria (CTC). 2, 1-35. 30-4-1999. NCI; NIH; DCTD; DHHS. Cancer Therapy Evaluation Program. Common Toxicity Criteria, Version 2.0. 23-3-1998
80. Morton, D. L., Essner, R., Kirkwood, J. M. et al., Malignant Melanoma. In: Bast, R. C. Jr., Kufe, D. W., Pollock, R. E. et al. (eds.), Cancer Medicine. 5th ed., p. 1849-1869, B.C. Decker Inc., Hamilton, London (Canada) (2000)
81. Horwitz, R. I., Yu, E. C., Assessing the reliability of epidemiologic data obtained from medical records. J. Chronic Dis. 37, 825 (1984)
82. Velikova, G., Wright, P., Smith, A. B. et al., Self-reported quality of life of individual cancer patients: concordance of results with disease course and medical records. J. Clin. Oncol. 19, 2064 (2001)
83. Kleijnen, J., Knipschild, P., Mistletoe treatment for cancer: review of controlled trials in humans. Phytomedicine 1, 255 (1994)
84. Steuer-Vogt, M. K., Bonkowsky, V., Ambrosch, P. et al., The effect of an adjuvant mistletoe treatment programme in resected head and neck cancer patients: a randomised controlled clinical trial. Eur. J. Cancer 37, 23 (2001)
85. Grossarth-Maticek, R., Kiene, H., Baumgartner, M. et al., Use of Iscador, an extract of European mistletoe (Viscum album), in cancer treatment: prospective nonrandomized and randomized matched-pair studies nested within a cohort study. Altern. Ther. in Health Med. 7, 57 (2001)
86. Lenartz, D., Dott, U., Menzel, J., Schierholz, J. M. et al., Survival of glioma patients after complementary treatment with galactoside-specific lectin from mistletoe. Anticancer Res. 20, 2073 (2000)
87. Gorter, R. W., van Wely, M., Reif, M. et al., Tolerability of an extract of European mistletoe among immunocompromised and healthy individuals. Altern. Ther. Health Med. 5, 37 (1999)
88. Hutt, N., Kopferschmitt-Kubler, M., Cabalion, J. et al., Anaphylactic reactions after therapeutic injection of mistletoe (Viscum album L.). Allergol Immunopathol (Madrid) 29, 201 (2001)
89. van Wely, M., Stoss, M., Gorter, R. W., Toxicity of a standardized mistletoe extract in immunocompromised and healthy individuals. Am. J. Ther. 6, 37 (1999)
90. Eggermont, A. M., Kleeberg, U. R., Suciu, S. et al., The trial authors reply. Lancet Oncol. 2, 333 (2001)
91. Kleeberg, U. R. et al. Adjuvant trial in melanoma patients comparing rIFN-alpha to rIFN-gamma to Iscador to a control group after curative resection of high risk primary (>= 3 mm) or regional lymph node metastasis (EORTC 18871). Eur. J. Cancer 35, S82 (1999)